Atlas Capital Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.14M | Sell |
8,213
-21
| -0.3% | -$2.94K | 0.13% | 128 |
|
|
2025
Q4 | $1.01M | Buy |
+8,234
| New | +$1M | 0.11% | 151 |
|
|
2025
Q2 | $943K | Sell |
8,509
-1,638
| -16% | -$174K | 0.12% | 155 |
|
|
2025
Q1 | $1.14M | Buy |
10,147
+1,505
| +17% | +$155K | 0.14% | 135 |
|
|
2024
Q4 | $798K | Sell |
8,642
-231
| -3% | -$20.8K | 0.1% | 171 |
|
|
2024
Q3 | $744K | Buy |
8,873
+3,904
| +79% | +$298K | 0.11% | 161 |
|
|
2024
Q2 | $341K | Sell |
4,969
-1,128
| -19% | -$75.3K | 0.04% | 304 |
|
|
2024
Q1 | $447K | Sell |
6,097
-1,007
| -14% | -$77.4K | 0.07% | 235 |
|
|
2023
Q4 | $575K | Buy |
7,104
+534
| +8% | +$41.6K | 0.08% | 192 |
|
|
2023
Q3 | $492K | Sell |
6,570
-228
| -3% | -$17.5K | 0.08% | 191 |
|
|
2023
Q2 | $524K | Sell |
6,798
-1,700
| -20% | -$136K | 0.08% | 198 |
|
|
2023
Q1 | $705K | Sell |
8,498
-7,030
| -45% | -$582K | 0.11% | 140 |
|
|
2022
Q4 | $1.33M | Buy |
15,528
+9,705
| +167% | +$769K | 0.22% | 88 |
|
|
2022
Q3 | $359K | Sell |
5,823
-1,833
| -24% | -$116K | 0.07% | 231 |
|
|
2022
Q2 | $473K | Buy |
7,656
+66
| +0.9% | +$4.09K | 0.08% | 206 |
|
|
2022
Q1 | $451K | Hold |
7,590
| – | – | 0.07% | 222 |
|
|
2021
Q4 | $551K | Hold |
7,590
| – | – | 0.08% | 201 |
|
|
2021
Q3 | $530K | Hold |
7,590
| – | – | 0.09% | 194 |
|
|
2021
Q2 | $523K | Buy |
7,590
+74
| +1% | +$4.94K | 0.09% | 197 |
|
|
2021
Q1 | $486K | Buy |
7,516
+1,818
| +32% | +$117K | 0.09% | 198 |
|
|
2020
Q4 | $332K | Buy |
5,698
+203
| +4% | +$12.2K | 0.07% | 238 |
|
|
2020
Q3 | $347K | Sell |
5,495
-618
| -10% | -$42.9K | 0.08% | 231 |
|
|
2020
Q2 | $470K | Hold |
6,113
| – | – | 0.11% | 191 |
|
|
2020
Q1 | $457K | Hold |
6,113
| – | – | 0.14% | 165 |
|
|
2019
Q4 | $397K | Hold |
6,113
| – | – | 0.1% | 221 |
|
|
2019
Q3 | $387K | Buy |
6,113
+1,202
| +24% | +$78.6K | 0.12% | 221 |
|
|
2019
Q2 | $332K | Hold |
4,911
| – | – | 0.11% | 223 |
|
|
2019
Q1 | $319K | Sell |
4,911
-2,068
| -30% | -$137K | 0.12% | 205 |
|
|
2018
Q4 | $437K | Sell |
6,979
-3,915
| -36% | -$274K | 0.17% | 154 |
|
|
2018
Q3 | $861K | Buy |
10,894
+1,983
| +22% | +$150K | 0.29% | 91 |
|
|
2018
Q2 | $688K | Sell |
8,911
-13,730
| -61% | -$970K | 0.24% | 115 |
|
|
2018
Q1 | $1.71M | Buy |
+22,641
| New | +$1.8M | 0.52% | 41 |
|
Other funds holding GILD
VCM
VPM
Atlas Capital Advisors's GILD Position: Q1 2026 in Review
Atlas Capital Advisors reduced its Gilead Sciences (GILD) stake by 0.26% in Q1 2026, selling an estimated $2.94K and leaving 8,213 shares worth $1.14M. The position accounts for 0.13% of the portfolio, ranked #128.
Atlas Capital Advisors first reported a position in GILD in Q1 2018 and has held it in 32 quarters since. The position peaked at $1.71M in Q1 2018. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Atlas Capital Advisors held 8,213 shares of Gilead Sciences worth $1.14M as of Q1 2026.
- Atlas Capital Advisors sold 21 Gilead Sciences shares in Q1 2026, an estimated $2.94K.
- Gilead Sciences made up 0.13% of Atlas Capital Advisors's portfolio in Q1 2026, its #128 holding.
- Atlas Capital Advisors first reported a position in Gilead Sciences in Q1 2018 and has held it in 32 quarters since.
- Atlas Capital Advisors's Gilead Sciences position peaked at $1.71M in Q1 2018.
- 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Atlas Capital Advisors's 13F filing for Q1 2026, filed 11 May 2026.